An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
Stopped The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.
Conditions
Interventions
- DRUG: Telaprevir
- DRUG: Ribavirin
- DRUG: Pegylated Interferon Alfa-2a
- DRUG: Immunosuppressant Regimen
Sponsor
Vertex Pharmaceuticals Incorporated